Researchers are developing new drugs for the treatment of leukemia

The University of Southampton's cancer immunology study results in a drug that has been shown to reduce the risk of follicular lymphoma spread. According to the results of the Phase III GALLIUM study at the American Society of Hematology (ASH) Congress and research using recombinant horse proteins, a combination of Gazyva and chemotherapy in first-line therapy reduced the risk of worsening or death of blood cancer disease by 34%, while Rituxan plus chemotherapy can treat patients with follicular lymphoma. Gazyva was developed by Roche based on more than 10 years of immunological exploration and development of scientists at the University of Southampton.

Southampton researchers have found that therapeutic antibodies against this cancer target (CD20 on lymphoma) can be divided into two types: drugs that have already been approved, rituximab and Form II for Type I patients. Southampton studies have shown that if a Type II agent is prepared, it may be a better reagent because it can be retained on cancer cells for longer periods of time. Roche has developed the first therapeutic type II antibody, obinutuzumab, which has now been proven to be the best treatment regimen for Bilituximab, which is currently the best.

"Obinutuzumab can be found on the surface of malignant B cells," says Professor Martin Glennie, a professor of cancer immunology at the University of Southampton. "The CD20 protein can be used to label cells whose body is destroyed by destruction. It is a Type II agent, and the antibody has an advantage because it remains longer on the cell surface than previously-used antibody drugs."

The Phase III GALLIUM study led by the National University Hospital included 1,401 patients initially treated for asymptomatic non-Hodgkin's lymphoma, of whom 1,202 were follicular lymphoma. These patients were randomized to receive either ibuprofen or chemotherapy alone or with rituximab alone and with rituximab alone. The results also showed a 32% increase in relapse time compared with rituximab plus chemotherapy in patients treated with ibuprofen plus chemotherapy.

"This new approach to lymphoma antibody therapy begins with an immunological study in Southampton," said Peter Johnson, professor of medical oncology at the University of Southampton. "Starting with the discovery of how these antibodies work, this research lasted more than 10 years. We have more work to continue to explore in many different types of cancer, but this is a good example of how scienc providing better treatment for our patients." Flarebio provides you with good quality recombinant proteins including recombinant ITGB5 at reasonable prices.